RXII - RXi Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue151934
Cost of Revenue---
Gross Profit151934
Operating Expenses
Research Development5,3705,4156,925
Selling General and Administrative4,0113,6193,346
Non Recurring4,6964,6964,696
Others---
Total Operating Expenses---
Operating Income or Loss-14,062-9,015-10,237
Income from Continuing Operations
Total Other Income/Expenses Net-10614
Earnings Before Interest and Taxes-14,073-8,994-10,223
Interest Expense---
Income Before Tax-14,073-8,994-10,223
Income Tax Expense-1,621--
Minority Interest---
Net Income From Continuing Ops-12,452-8,994-10,223
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-12,452-8,994-10,223
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-12,452-11,069-10,432